Click here and sign up now
Driving post-COVID cancer treatment with innovation and dedication
Cancer immunotherapy is a staple of modern oncology. But how did the concept move from from far-fetched concept to medical reality?
Therapeutic cancer vaccine trials have an opportunity to leverage recent interest in vaccine technology to make headway in oncology, says Advanced Clinical’s Christopher Oelkrug
Daily and weekly email newsletters from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry
Founder and president of clinical development analytics company Phesi Dr Gen Li discusses prominent challenges and opportunities in oncology trials
Kidney cancer care in the UK is reaching a tipping point. IPSEN’s Siew Kwan Chang discusses the need for dedicated NICE guidance for kidney cancer
Diversity is no longer an optional luxury in clinical research, explain Dr Stephen Keith and Nick Kenny from Syneos. But what can be done to improve DE&I in oncology trials?
Download exclusive interviews and discussions with senior pharma and biotech executives
The UK has a rich history of advancing genomics research, which has opened the door for routine genomic testing for cancer, as IQVIA’s Orlaith Brennan and Dr Julia Beguería explain
Recent progress in immunotherapy, targeted therapies, and genetic testing has allowed physicians to treat breast cancer more precisely, says Daiichi Sankyo’s Markus Kosch
pharmaphorum editor in chief Jonah Comstock rounds up key developments from the American Society of Clinical Oncology’s first in-person conference since COVID began
Frontiers Health returns for a two-day hybrid event, with super early bird passes now on sale
Sign-up to receive the next issue of pharmaphorum’s digital magazine for pharma direct to your inbox
E-mail address receiver
Thank you for your feedback.